No Data
No Data
Express News | Praxis Precision Medicines : Sales Agreement Prospectus Covering Offering up to $250 Mln of Common Stock That May Be Issued From Time to Time
Express News | Praxis Precision Medicines Inc Files for Mixed Shelf- SEC Filing
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Praxis Precision Medicines (PRAX) Gets a Buy From Truist Financial
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025
Express News | Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
No Data
BarfBag : Check out $Pagaya Technologies (PGY.US)$ solid AH